We have been selected by Ipsen, one of the world’s leading innovators in patient care, as their chosen strategic partner in Europe for executive talent acquisition within their Specialty Care division.
Ipsen has recently licenced the best in class, launch-ready Cabozantinib from Exelixis. An asset with outstanding data in the attractive RCC field, the product has triggered a treatment paradigm shift and Ipsen’s timelines for launch are extremely short with time to hire critical to be ready to go to market.
With over 30 senior positions to fill within very short timelines, we were chosen for our reach across Europe and our unique Proof of Candidate® process which Ipsen recognised would enhance their profile, increase their visibility amongst a specialised talent pool and ensure they attract the most talented candidates in oncology.
If you would like to learn more about Proof of Candidate®, our due diligence approach to helping you choose and keep the most talented candidates, please get in touch with your local office or partner.